Target intelligence / Profile preview

DNAJC9 antisense RNA 1 (DNAJC9-AS1)

Target
DNAJC9-AS1
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA
01

Overview

DNAJC9 antisense RNA 1 (DNAJC9-AS1) is a long non-coding RNA (lncRNA) gene located on human chromosome 10 and annotated in major genomic databases (NCBI Gene ID: 414245, Ensembl: ENSG00000236756)[1][5][9]. It is transcribed as an antisense RNA relative to its neighboring DNAJC9 and MRPS16 genes. The known aliases for this gene include C10orf103 and bA537A6.3[1][5][6][9]. DNAJC9-AS1 is classified as a lncRNA, not as a protein-coding gene[2][9]. It is reported to be involved in **basic cellular processes** including cell proliferation, apoptosis, and migration[2]. The mechanistic details of its function are largely unexplored; however, like other lncRNAs, DNAJC9-AS1 is predicted to participate in **chromatin regulation** and **transcription factor modulation**[1]. These roles are based on dataset associations, histone modification site profiles, and transcription factor binding evidence at the gene’s promoter[1]. Clinical and experimental evidence for DNAJC9-AS1’s role in **disease** is limited. Some databases note a weak association with **glioma susceptibility**[9], and by analogy with other lncRNAs, there may be relevance in broader cancer contexts, but robust data are lacking[2]. There are **no known drugs** that directly interact with DNAJC9-AS1, nor established mechanisms of drug action, known biomarkers, or documented safety concerns[1][2][9]. This molecule is **not considered a conventional therapeutic target** (such as a receptor, enzyme, or transporter)[1][2][9]. Most research concerning DNAJC9-AS1 remains descriptive, focusing on expression profiles across tissues and cells, rather than on pharmacological or clinical targeting. In summary, **DNAJC9 antisense RNA 1 (DNAJC9-AS1)** is a long non-coding RNA with unclear and incompletely characterized molecular function, mainly implicated in general cellular regulatory processes and not considered a therapeutic target at present[1][2][9].

Other names
C10orf103bA537A6.3DNAJC9 and MRPS16 antisense RNA 1DNAJC9 antisense gene protein 1
02

Biological functions

Cell proliferationApoptosisMigrationPossible involvement in chromatin regulation and transcription factor binding
03

Disease associations

Glioma susceptibility (weak association)Potential relevance in other cancers (inferred from lncRNA roles in cancer, but specific evidence for DNAJC9-AS1 is sparse)

Beyond the preview

Go deeper on DNAJC9 antisense RNA 1 (DNAJC9-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNAJC9 antisense RNA 1 (DNAJC9-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call